|
Re: Financials
|
1
|
Resverlogix Corp.
|
Aug 17, 2021 11:32AM
|
|
Re: Financial Statement Q2, 2023 /MD&A
|
3
|
Resverlogix Corp.
|
Aug 12, 2023 07:07PM
|
|
Re: Financial Statement Q2, 2023 /MD&A
|
7
|
Resverlogix Corp.
|
Aug 13, 2023 12:51PM
|
|
Re: Finance
|
1
|
Resverlogix Corp.
|
Feb 23, 2021 04:50PM
|
|
Re: Finance
|
7
|
Resverlogix Corp.
|
Feb 10, 2021 10:34AM
|
|
Re: Finance
|
3
|
Resverlogix Corp.
|
Oct 29, 2017 11:04AM
|
|
Re: FDA approves drug that reduces MACE in Diabetes patients (Forbes)
|
3
|
Resverlogix Corp.
|
Jun 15, 2016 11:31AM
|
|
Re: FDA approves drug that reduces MACE in Diabetes patients (Forbes)
|
3
|
Resverlogix Corp.
|
Jun 15, 2016 09:16AM
|
|
Re: Fair warning to everyone here....
|
5
|
Resverlogix Corp.
|
Jun 25, 2019 08:33AM
|
|
Re: Fabry trial news, Halifax and Alberta's Children't Hospital slated....
|
4
|
Resverlogix Corp.
|
Jun 14, 2017 03:44PM
|
|
Re: FA expectations
|
6
|
Resverlogix Corp.
|
Sep 20, 2017 10:13AM
|
|
Re: Exposure in Motley Fool....
|
1
|
Resverlogix Corp.
|
Oct 08, 2019 10:10PM
|
|
Re: Exposure in Motley Fool....
|
2
|
Resverlogix Corp.
|
Oct 09, 2019 08:08AM
|
|
Re: Exempt Distribution - 2022-04-14
|
6
|
Resverlogix Corp.
|
Apr 19, 2022 12:08PM
|
|
Re: Eversana ValuationCaseStudy
|
11
|
Resverlogix Corp.
|
Jan 08, 2022 12:52PM
|
|
Re: Eversana ValuationCaseStudy
|
6
|
Resverlogix Corp.
|
Jan 09, 2022 06:29PM
|
|
Re: Eversana ValuationCaseStudy
|
3
|
Resverlogix Corp.
|
Jan 04, 2022 01:16PM
|
|
Re: Evacetrapib fails
|
2
|
Resverlogix Corp.
|
May 18, 2017 10:35AM
|
|
Re: European Atherosclerosis Society Congress May 29 - June 1
|
4
|
Resverlogix Corp.
|
May 27, 2016 05:00PM
|
|
Re: Est. Cash Position
|
4
|
Zenith Epigenetics
|
Apr 27, 2021 10:18AM
|
